DBV Technologies Shares Drop 2.5% and Test €2.75 Support Level
French biotech company DBV Technologies sees a midday decline, contrary to the nearly stable SBF 120. The stock is testing a technical threshold that has been monitored for several weeks, amid increased selling pressure.
The stock briefly dips below its €2.75 support before recovering
DBV Technologies' shares fell 2.34% to €2.75 during the session, after hitting a low of €2.73, thus falling below its €2.75 support level before returning to this threshold. The stock remains down 15.88% over one month and 18.16% over three months, while still posting a gain of more than 67% over one year. The RSI at 39 reflects the recent selling pressure without reaching the oversold zone, as the share price is 9.11% below its 200-day moving average (€3.03), a threshold it crossed downwards at the beginning of June. The biotech is thus among the largest declines in the SBF 120 at mid-session, in a Paris market that remains close to equilibrium.
Short seller pressure significantly increases over a month
According to reviewed statements, four funds now hold a combined 3.96% of DBV Technologies' capital in net short positions, up from 2% a month ago (an increase of nearly two percentage points in thirty days). This rapid rise reflects a strengthening of bearish bets on the stock, even though the biotech remains below all its moving averages. The recent context is marked by clinically positive announcements about the Viaskin Peanut program, with phase 3 VITESSE study data unveiled on June 8 and presented at the EAACI congress.
The dual listing in Paris and on the Nasdaq (under the ticker DBVT, with one ADS for every five ordinary shares since November 2024) maintains a strong correlation between the two markets. The holding of the €2.75 support level, already tested during the session, remains the technical level to watch going forward.
